Affiliations: [a]
Department of Neurology, Hospital Clinico San Carlos, San Carlos Institute for Health Research (IdiSSC), Universidad Complutense, Madrid, Spain
| [b]
Faculty of Psychology, Universidad Autónoma de Madrid, Madrid, Spain
| [c]
Department of Computer Architecture and Automation, Faculty of Informatics, Universidad Complutense, Madrid, Spain
Correspondence:
[*]
Correspondence to: Jordi A. Matias-Guiu, Department of Neurology, Hospital Clinico San Carlos, Profesor Martin Lagos St., ES-28040, Spain. E-mails: jordimatiasguiu@hotmail.com; jordi.matias-guiu@salud.madrid.org; ORCID: 0000-0001-5520-2708.
Abstract: Background:The Rowland Universal Dementia Assessment Scale (RUDAS) is a cognitive test with favorable diagnostic properties for detecting dementia and a low influence of education and cultural biases. Objective:We aimed to validate the RUDAS in people with Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Methods:We enrolled one hundred and fifty participants (60 with AD, 30 with PD, 60 with MS, and 120 healthy controls (HC)). All clinical groups completed a comprehensive neuropsychological battery, RUDAS, and standard cognitive tests of each disorder: MMSE, SCOPA-COG, and Symbol Digit Modalities Test. Intergroup comparisons between clinical groups and HC and ROC curves were estimated. Random Forest algorithms were trained and validated to detect cognitive impairment using RUDAS and rank the most relevant scores. Results:The RUDAS scores were lower in patients with AD, and patients with PD and MS showed cognitive impairment compared to healthy controls. Effect sizes were generally large. The total score was the most discriminative, followed by the memory score. Correlations with standardized neuropsychological tests were moderate to high. Random Forest algorithms obtained accuracies over 80–90% using the RUDAS for diagnosing AD and cognitive impairment associated with PD and MS. Conclusion:Our results suggest the RUDAS is a valid test candidate for multi-disease cognitive screening tool in AD, PD, and MS.
